Long-Term Outcomes after Switching to Tenofovir Alafenamide in Patients with Chronic Hepatitis B.

Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE

Original Publication: Basel, Switzerland : MDPI, [2000-

Antiviral Agents*/adverse effects ; Hepatitis B, Chronic*/drug therapy; Humans ; Middle Aged ; Tenofovir/adverse effects ; Hepatitis B Surface Antigens ; Hepatitis B e Antigens ; DNA, Viral ; Alanine/therapeutic use ; Adenine/therapeutic use ; Treatment Outcome

We sought to determine the long-term outcomes of chronic hepatitis B (CHB) cases switching to tenofovir alafenamide (TAF, n = 104, median age = 63.5 years). Data at switching to TAF (baseline) and those at 1, 2, 3, 4, and 5 years from switching to TAF were compared. At baseline, HB envelop antigen (HBeAg) seropositivity was found in 20 patients (19.2%), and undetectable HBV-DNA in 77 patients (74.0%). Percentage of detectable HBV-DNA significantly reduced at any time point. HB surface antigen (HBsAg) levels significantly reduced at 3, 4, and 5 years. The percentage of HBeAg seropositivity significantly reduced at 5 years. HB core related antigen levels did not significantly change. In patients with baseline HbeAg seropositivity, HbsAg levels significantly reduced at any time point, and a similar trend was found in patients without HBeAg seropositivity. In patients with baseline FIB4 index >1.85, HBsAg levels significantly reduced at 3, 4, and 5 years, and in patients with baseline FIB4 index <1.85, HBsAg levels significantly reduced at any time point. The estimated glomerular filtration rate significantly reduced only at 5 years. The discontinuation rate owing to the side effects of TAF was 0%. In conclusion, switching to TAF therapy in patients with CHB may be effective and safe at least up to 5 years.

Hepatol Res. 2014 Jun;44(6):608-20. (PMID: 23701455)
World J Gastroenterol. 2016 Feb 14;22(6):1943-52. (PMID: 26877602)
Aliment Pharmacol Ther. 2014 Feb;39(4):349-58. (PMID: 24387289)
Clin Gastroenterol Hepatol. 2022 Feb;20(2):427-437.e5. (PMID: 33962041)
PLoS One. 2022 Jan 20;17(1):e0261760. (PMID: 35051189)
J Viral Hepat. 2019 May;26(5):561-567. (PMID: 30576085)
Am J Gastroenterol. 2023 Aug 10;:. (PMID: 37561058)
Eur J Gastroenterol Hepatol. 2021 Dec 1;33(1S Suppl 1):e898-e904. (PMID: 35048656)
J Hepatol. 2018 Apr;68(4):672-681. (PMID: 29756595)
Lancet. 2023 Mar 25;401(10381):1039-1052. (PMID: 36774930)
Nat Rev Gastroenterol Hepatol. 2023 Apr;20(4):238-253. (PMID: 36631717)
Hepatol Res. 2019 Mar;49(3):271-283. (PMID: 30358027)
Viruses. 2022 Feb 21;14(2):. (PMID: 35216027)
Liver Int. 2021 Jun;41(6):1254-1264. (PMID: 33404182)
Lancet Gastroenterol Hepatol. 2020 May;5(5):441-453. (PMID: 32087795)
Aliment Pharmacol Ther. 2022 Aug;56(4):713-722. (PMID: 35735794)
Hepatol Res. 2020 Aug;50(8):892-923. (PMID: 32343469)
Rev Med Virol. 2022 Nov;32(6):e2353. (PMID: 35441759)
Clin Mol Hepatol. 2023 Oct;29(4):851-868. (PMID: 36891607)
Lancet Gastroenterol Hepatol. 2016 Nov;1(3):185-195. (PMID: 28404091)
JGH Open. 2019 Oct 24;4(3):429-432. (PMID: 32514449)
J Hepatol. 2021 Aug;75(2):302-310. (PMID: 33762167)
J Hepatol. 2015 Mar;62(3):533-40. (PMID: 25450717)
Aliment Pharmacol Ther. 2024 Jan;59(2):239-248. (PMID: 37882252)
Lancet Gastroenterol Hepatol. 2022 Sep;7(9):796-829. (PMID: 35738290)
J Hepatol. 2022 Jun;76(6):1249-1262. (PMID: 35589248)
J Hepatol. 2016 Jul;65(1):48-56. (PMID: 27034253)

Keywords: chronic hepatitis B; efficacy; safety; switch; tenofovir alafenamide

99YXE507IL (Tenofovir)
0 (Antiviral Agents)
0 (Hepatitis B Surface Antigens)
0 (Hepatitis B e Antigens)
0 (DNA, Viral)
OF5P57N2ZX (Alanine)
JAC85A2161 (Adenine)

Date Created: 20240224 Date Completed: 20240226 Latest Revision: 20240227

20240227

PMC10888772

10.3390/ijms25042245

38396921